Company: SMNR
Filing Date: 2025-10-21
Form Type: S-1
Source: 0001193125-25-245178
Chunk: 285

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-10-21
Form: S-1
Chunk 285
---
ies with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and Nasdaq Listing Rules. Semnur intends to comply with future requirements to the extent they become applicable to Semnur. Compensation Committee Semnur’s Compensation Committee consists of Jay Chun, M.D., Ph.D., Dorman Followwill and Yue Alexander Wu, Ph.D., with Yue Alexander Wu, Ph.D. serving as the chairperson of the committee. Jay Chun, M.D., Ph.D., Dorman Followwill and Yue Alexander Wu, Ph.D. each satisfy the independence requirements under the Nasdaq Listing Rules. Each of the members of the Compensation Committee are non-employee director as defined in Rule 16b-3 promulgated under the Exchange Act and satisfy Nasdaq independence requirements. The Compensation Committee acts on behalf of the Board to fulfill the Board’s responsibilities in overseeing the company’s compensation policies, plans and programs; and in reviewing and determining the compensation to be paid to the executive officers and non-employee directors of Semnur. The responsibilities of the Compensation Committee are included in its written charter. The Compensation Committee’s responsibilities include, among others:

| • |     | reviewing, modifying and approving (or, if it deems appropriate, making recommendations to the Board regarding) Semnur’s overall compensation strategy and policies, to assure that they promote stockholder interests and support the Company’s strategic and tactical objectives, and that they provide for appropriate rewards and incentives for the Company’s management and employees; |

| • |     | reviewing, modifying and approving corporate performance goals and objectives relevant to the compensation of Semnur’s executive officers and other senior management; |

| • |     | determining and approving (or, if it deems appropriate, recommending to the Board for determination and approval) the compensation and terms of employment of Semnur’s Chief Executive Officer, including seeking to achieve an appropriate level of risk and reward in determining the long-term incentive component of the compensation of the Chief Executive Officer; |

| • |     | determining and approving (or, if it deems appropriate, recommending to the Board for determination and approval) the compensation and terms of employment of Semnur’s executive officers and other members of senior management; |

| • |     | reviewing and approving (or, if it deems appropriate, making recommendations to the Board regarding) the terms of employment agreements and severance agreements, |

| • |     | change-of-control protections and other compensatory arrangements for Semnur’s executive officers